This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Phase I Study of Cisplatin Plus OSI-7904L in Patients With Solid Tumors

This study has been completed.
Information provided by:
OSI Pharmaceuticals Identifier:
First received: June 30, 2005
Last updated: January 16, 2009
Last verified: November 2003
This is a Phase I, open-label, dose escalation, study of the combination of cisplatin and OSI-7904L given on Day 1 every 21 days in patient who have advanced solid tumors.

Condition Intervention Phase
Advanced Solid Tumors Drug: OSI-7904L Drug: Cisplatin Phase 1

Study Type: Interventional
Study Design: Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I Study of OSI-7904L in Combination With Cisplatin in Patients With Advanced Solid Tumors

Resource links provided by NLM:

Further study details as provided by OSI Pharmaceuticals:

Estimated Enrollment: 25
Study Start Date: June 2003
Estimated Study Completion Date: December 2004

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 18 years of age or older
  • Advanced and/or metastatic solid tumor for which no effective therapy is available
  • ECOG performance status 0-2
  • Adequate bone marrow, hepatic and renal function

Exclusion Criteria:

  • Patients with active or uncontrolled infections
  • Neurotoxicity >= Grade 2
  • Symptomatic brain metastases which are not stable
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00116896

United States, Tennessee
Vanderbilt Universtiy Medical Center
Nashville, Tennessee, United States, 37232-6307
United States, Texas
Institute for Drug DevelopmentCancer Therapy & Research Center
San Antonio, Texas, United States, 78229
Sponsors and Collaborators
OSI Pharmaceuticals
  More Information Identifier: NCT00116896     History of Changes
Other Study ID Numbers: OSI-904-102
Study First Received: June 30, 2005
Last Updated: January 16, 2009

Additional relevant MeSH terms:
Antineoplastic Agents processed this record on August 21, 2017